CACI Joins the Fortune 500 List of America's Largest Companies
RESTON, Va.--(BUSINESS WIRE)--CACI International Inc (NYSE: CACI) announced today that it has been named a 2025 Fortune 500™ company. The Fortune 500 is an annual list of the largest corporations in the United States and CACI was ranked based on its impressive 2024 fiscal year (FY24) results.
'CACI is proud to join the prestigious Fortune 500 list following an historic year of growth,' said CACI President and Chief Executive Officer John Mengucci. 'This accomplishment is a testament to our vision of delivering critical expertise and technology to protect our nation and meet our customer commitments—both of which drove the financial performance that led to this recognition.'
'CACI has an unwavering commitment to national security that is built upon a six-decade foundation of character and innovation. We offer rapidly deployable, software-based critical technology coupled with the intrinsic mission knowledge that only CACI can provide, so our customers can remain focused on safeguarding our nation. This achievement reflects the tough, challenging work that occurs at our company on a daily basis, and it belongs to every one of our incredibly talented and dedicated employees who are at the cornerstone of our success,' said Mengucci.
CACI continuously strives to deliver strong operational excellence and shareholder value. Today's announcement reflects CACI's significant growth and relentless drive to fulfill its strategic objectives in FY24, which drove $7.7 billion in revenue, representing a 14% year-over-year increase. The revenue threshold for the 2025 Fortune 500 list was $7.4 billion.
CACI also recently earned its 14 th recognition as a Fortune World's Most Admired Company.
About CACI
At CACI International Inc (NYSE: CACI), our 25,000 talented and dynamic employees are ever vigilant in delivering distinctive expertise and differentiated technology to meet our customers' greatest challenges in national security. We are a company of good character, relentless innovation, and long-standing excellence. Our culture drives our success and earns us recognition as a Fortune World's Most Admired Company. CACI is a member of the Fortune 500™ list of largest companies, the Russell 1000 Index, and the S&P MidCap 400 Index. For more information, visit us at www.caci.com.
There are statements made herein which do not address historical facts, and therefore could be interpreted to be forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements are subject to factors that could cause actual results to differ materially from anticipated results. The factors that could cause actual results to differ materially from those anticipated include, but are not limited to, the risk factors set forth in CACI's Annual Report on Form 10-K for the fiscal year ended June 30, 2024, and other such filings that CACI makes with the Securities and Exchange Commission from time to time. Any forward-looking statements should not be unduly relied upon and only speak as of the date hereof.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CNBC
11 minutes ago
- CNBC
The biggest risk to valuations is what happens to 10-year rates, says Barclays' Venu Krishna
Venu Krishna, Barclays head of U.S. Equity Strategy, joins 'The Exchange' to discuss Barclays lifting it S&P target to 6,050.
CNBC
11 minutes ago
- CNBC
Health care stocks are due for a turnaround after a historically bad month, according to the charts
The Health Care Select Sector SPDR Fund (XLV) was down over 5% in May, as the S & P 500 gained over 6%, which means that XLV underperformed the index by 11%. That's a huge performance discrepancy. In fact, it was the worst relative monthly percent move vs. the SPX in XLV's history, dating back to late 1998. As is clear from this long-term chart, the odds of this horribly bad relative weakness continuing at this same pace is low – at least for June. XLV itself now has approached two major long-term support levels after the recent downturn. The first is the rising trendline that begins at the 2009 financial crisis low and extends through the Covid bottom. XLV tested this line in mid-May, bounced and finished the month modestly off its lows. The second key support zone comes from the cluster of lows in 2021, 2022 and 2023, noted by the horizontal line that's in the low 120s. The converging lines present a confluence of support that clearly could help XLV's bouncing prospects in June. XLV: The 3 biggest holdings Believe it or not, 34 of XLV's 61 components actually logged gains in May. That's encouraging, but we'll need to see its biggest holdings respond soon. If they can't rally, XLV will continue to struggle. The three largest stocks within the ETF are Eli Lilly , Johnson & Johnson and AbbVie , which make up nearly 27% of XLV combined. So, what are the odds that all three stocks actually can mount strong up-moves in June? Let's take a closer look. We'll start with LLY since it's XLV's biggest component, with a 12% weighting. LLY last made an all-time high in August 2024. From that peak to its April low, the stock lost 30%. But as the following weekly chart (in log scale) shows, it wasn't straight down from there. LLY logged various rallies and drawdowns since then, all of which have taken place within the pictured downward sloping trading channel. The best time to buy LLY, thus, has been after a big, long decline. The stock just fell another 20% from April 30 through May 25. As we can see, the past ensuing bounces yielded big percentage moves, even if they ultimately failed to break through the channel's upper threshold. Additionally, LLY's weekly Williams %R indicator (on the lower panel) is emerging from an oversold condition, which has supported three of the last four big up-moves. In fact, LLY quietly has logged gains in six of the last seven trading days. That's a good start. JNJ (7.7% weight) has been trending lower since topping in 2022, while ABBV (6.8%) has been in a clear uptrend the last few years. However, both have experienced various swings within their respective long-term trading channels — like LLY. And with both JNJ and ABBV having sold off from their 2025 highs, now would be an opportune time for the next bounce to commence. From a big picture market perspective, rotation is an important component of true, long-lasting uptrends. Thus, if/when the air comes out of the more extended sectors and groups soon, capital could find its way to the underperforming areas, which of course, includes health care. DISCLOSURES: None. All opinions expressed by the CNBC Pro contributors are solely their opinions and do not reflect the opinions of CNBC, NBC UNIVERSAL, their parent company or affiliates, and may have been previously disseminated by them on television, radio, internet or another medium. THE ABOVE CONTENT IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY . THIS CONTENT IS PROVIDED FOR INFORMATIONAL PURPOSES ONLY AND DOES NOT CONSITUTE FINANCIAL, INVESTMENT, TAX OR LEGAL ADVICE OR A RECOMMENDATION TO BUY ANY SECURITY OR OTHER FINANCIAL ASSET. THE CONTENT IS GENERAL IN NATURE AND DOES NOT REFLECT ANY INDIVIDUAL'S UNIQUE PERSONAL CIRCUMSTANCES. THE ABOVE CONTENT MIGHT NOT BE SUITABLE FOR YOUR PARTICULAR CIRCUMSTANCES. BEFORE MAKING ANY FINANCIAL DECISIONS, YOU SHOULD STRONGLY CONSIDER SEEKING ADVICE FROM YOUR OWN FINANCIAL OR INVESTMENT ADVISOR. Click here for the full disclaimer.
Yahoo
14 minutes ago
- Yahoo
Sprinklr (CXM) Stock Trades Up, Here Is Why
Shares of customer experience software provider Sprinklr (NYSE:CXM) jumped 5.7% in the morning session after the company reported a "beat-and-raise" quarter (Q1 FY-26). Sprinklr raised its full-year revenue and EPS guidance, which blew past analysts' expectations. The quarter was also solid as its revenue, EPS, and adjusted operating income exceeded Wall Street's estimates. The big win came on margins. Operating margin on a non-GAAP basis climbed to 18% from 11% last year, helped by pulling back on sales and marketing costs. That made a real difference in earnings per share, which jumped more than 30% and blew past Wall Street's estimates. Overall, we think this was a solid "beat-and-raise" quarter. After the initial pop the shares cooled down to $8.75, up 2.2% from previous close. Is now the time to buy Sprinklr? Access our full analysis report here, it's free. Sprinklr's shares are somewhat volatile and have had 12 moves greater than 5% over the last year. In that context, today's move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business. The biggest move we wrote about over the last year was 12 months ago when the stock dropped 24.2% on the news that the company reported weak first quarter results and provided full-year revenue guidance below expectations after being lowered. Also, its revenue guidance for next quarter missed Wall Street's estimates. The company called out a soft demand environment with longer sales cycles and heightened budgetary scrutiny. In addition, it observed higher churn in its core product suites due to reduced marketing spend, elimination of programs, and seat reductions. These issues contributed to the weak guidance as management expects the elevated churn level to continue for the full year FY '25. On the other hand, Sprinklr recorded significant improvement in new large contract wins. Overall, the guidance was quite bad and weighed on the stock. Following the results, D.A. Davidson downgraded the stock's rating from Buy to Neutral, while Cantor Fitzgerald also lowered the rating from Overweight to Neutral. Sprinklr is up 2.4% since the beginning of the year, but at $8.75 per share, it is still trading 19.3% below its 52-week high of $10.84 from June 2024. Investors who bought $1,000 worth of Sprinklr's shares at the IPO in June 2021 would now be looking at an investment worth $496.87. Unless you've been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story.
